Home > Insider Trading > Filing (0001567619-20-011544)

Filing Details

Accession Number:: 0001567619-20-011544
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-02 17:00:45
Reporting Period:: 2020-05-29

Accepted Time:: 2020-06-02 17:00:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1094176	Anne M Szostak	One Idexx Drive Westbrook ME 04092		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-05-29	7,722	$63.95	7,722	No	4	M	Direct
Common Stock	Disposition	2020-05-29	7,722	$0.00	0	No	4	G	Direct
Common Stock	Acquisiton	2020-05-29	7,722	$0.00	7,722	No	4	G	Indirect	M. Anne Szostak Trust
Common Stock	Disposition	2020-05-29	2,980	$306.12	4,742	No	4	S	Indirect	M. Anne Szostak Trust
Common Stock	Disposition	2020-05-29	3,052	$307.02	1,690	No	4	S	Indirect	M. Anne Szostak Trust
Common Stock	Disposition	2020-05-29	1,690	$308.08	0	No	4	S	Indirect	M. Anne Szostak Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	G	Direct
No	4	G	Indirect	M. Anne Szostak Trust
No	4	S	Indirect	M. Anne Szostak Trust
No	4	S	Indirect	M. Anne Szostak Trust
No	4	S	Indirect	M. Anne Szostak Trust

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right-to-buy)	Disposition	2020-05-29	7,722	$0.00	7,722	$63.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-05-05	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,217	Indirect	2020 Szostak IDEXX GRAT

Footnotes

The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.
The reporting person is the settlor and trustee of the 2020 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
Represents the weighted average price of the shares sold ranging from a low of $305.53 to a high of $306.52 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $306.67 to a high of $307.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $307.72 to a high of $308.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 3,861 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on May 6, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.